Check out our most popular compounded medications! Get Started
The Carbidopa 25 mg/Levodopa 100 mg Slow Release (MEM4) Oral Capsules are a specially formulated medication designed to manage the symptoms of Parkinson's disease and Parkinson's-like symptoms such as shakiness, stiffness, and difficulty moving. This formulation combines two active ingredients, Carbidopa and Levodopa, in a slow-release capsule format, providing a steady and prolonged release of the medication into the body.
Levodopa is converted into dopamine in the brain, helping to control movement and coordination. Carbidopa, on the other hand, prevents the breakdown of Levodopa in the bloodstream, allowing more Levodopa to reach the brain and thereby increasing its effectiveness. The combination of these two drugs helps to improve the symptoms of Parkinson's disease by increasing the amount of dopamine in the brain.
The unique feature of this formulation is the use of Methocel E4M, a type of controlled-release polymer. This polymer is designed to gradually release the encapsulated medication over an extended period of time. This slow-release mechanism offers sustained therapeutic effects, reducing the frequency of dosing and improving patient compliance, particularly beneficial for patients who have difficulty maintaining a regular medication schedule.
It's important to note that while this medication helps manage symptoms of Parkinson's, it does not cure the disease. Side effects may include nausea, vomiting, loss of appetite, and trouble sleeping. It's crucial to discuss these potential side effects with your healthcare provider to ensure this medication is the right choice for you.
As compounding pharmacists, we are committed to providing the highest quality medications tailored to individual patient needs. If you have any questions about the Carbidopa 25 mg/Levodopa 100 mg Slow Release (MEM4) Oral Capsules or any other medication, please don't hesitate to reach out to us at Bayview Pharmacy. We are here to help.
Carbidopa/Levodopa slow-release capsules are primarily used in the management of Parkinson's disease symptoms. This combination medication works by increasing the levels of certain chemicals in the brain that help with symptoms such as tremors, stiffness, and difficulty moving. Carbidopa helps to enhance the effects of Levodopa and reduce some of its side effects such as nausea and vomiting.
It's important to be aware of potential drug interactions that can affect the effectiveness of Carbidopa/Levodopa and increase the risk of side effects. Certain medications can interact with Carbidopa/Levodopa, including antipsychotic drugs (such as chlorpromazine, haloperidol), certain drugs used to treat high blood pressure (such as methyldopa, reserpine), and other drugs used to treat Parkinson's disease (such as selegiline, amantadine).
Do not start, stop, or change the dosage of any medicines without your doctor's approval. Some products that may interact with this drug include: certain antidepressants (including tricyclics such as amitriptyline, SSRIs such as fluoxetine), certain medications used to treat high blood pressure or irregular heartbeat (such as beta blockers like metoprolol, calcium channel blockers like verapamil), and certain antifungal medications (such as itraconazole, ketoconazole).
Carbidopa/Levodopa can also interact with certain dietary substances. For example, high-protein diets can decrease the absorption of Levodopa, which may reduce the effectiveness of this medication. It's recommended to have a balanced diet while taking this medication. Also, avoid taking supplements that contain iron, as iron can reduce the absorption of this medication.
It's also important to note that Carbidopa/Levodopa can cause a false result in certain lab tests for urine ketones. Make sure laboratory personnel and all your doctors know you use this drug.
Remember that your healthcare provider has prescribed this medication because they have judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. However, if you notice any side effects, contact your healthcare provider promptly.
If you have any questions about Carbidopa/Levodopa slow-release capsules, or about potential drug interactions, please don't hesitate to reach out to us at Bayview Pharmacy.
The Carbidopa 25 mg/Levodopa 100 mg Slow Release (MEM4) Oral Capsules work by combining two active ingredients, Carbidopa and Levodopa, in a controlled-release formulation. This formulation is designed to gradually release the medication over an extended period of time, providing sustained therapeutic effects and reducing the frequency of dosing. This is achieved through the use of Methocel E4M, a type of controlled-release polymer.
Levodopa is a medication that is converted into dopamine in the brain. Dopamine is a neurotransmitter that is essential for normal brain function, including the control of movement. In conditions such as Parkinson's disease, the amount of dopamine in the brain is reduced, leading to symptoms such as tremors, stiffness, and difficulty with movement. By providing a source of Levodopa, this medication helps to increase the levels of dopamine in the brain, thereby reducing these symptoms.
Carbidopa is included in this formulation to enhance the effectiveness of Levodopa. On its own, a large portion of Levodopa is broken down in the body before it can reach the brain. Carbidopa works by inhibiting this breakdown, allowing more Levodopa to reach the brain and be converted into dopamine. This means that lower doses of Levodopa can be used, reducing the risk of side effects.
The use of Methocel E4M in this formulation allows for a slow and controlled release of the active ingredients. This means that the medication is released gradually over time, providing a steady level of medication in the body. This can help to reduce fluctuations in symptoms and provide more consistent relief. It also means that the medication needs to be taken less frequently, which can improve patient compliance.
This formulation is used to treat conditions where there is a deficiency of dopamine in the brain, such as Parkinson's disease and certain forms of parkinsonism. It can help to reduce symptoms such as tremors, stiffness, and difficulty with movement, improving the quality of life for patients with these conditions.
If you have any questions about this formulation, or if you would like more information, please do not hesitate to reach out to us. We are here to help and provide you with the information you need to make informed decisions about your medication.
The carbidopa/levodopa slow-release oral capsules are primarily intended to manage the symptoms of Parkinson's disease by replacing lost dopamine in the brain, and preventing rapid breakdown of dopamine, which helps to improve motor function and ability to perform daily activities. However, given the mechanisms of carbidopa/levodopa, these capsules may have potential additional uses beyond the treatment of Parkinson's disease.
For instance, Carbidopa/Levodopa slow-release capsules could be used off-label to manage restless legs syndrome (RLS). People with RLS have uncomfortable sensations in their legs, leading to an overwhelming need to move them, especially at night or while resting. It is because the symptoms of RLS appear to arise from brain areas that are also affected by Parkinson's, and dopamine appears to be involved in both conditions. Carbidopa/levodopa medication can improve these symptoms by supplementing dopamine levels, leading to symptomatic relief.
Moreover, specific types of dystonia, a disorder characterized by involuntary muscle contractions, might respond to Carbidopa/Levodopa therapy. While it isn’t a definitive treatment for all cases, in some types of dystonia such as dopa-responsive dystonia (DRD), it may lead to significant improvement or even complete remission of the symptoms.
This drug must be administered under the supervision of a healthcare professional. It's important to note that the use of Carbidopa/Levodopa for conditions other than Parkinson's disease is considered an off-label use, and the effectiveness of the drug for these other conditions may vary from individual to individual. The dose and dosage regimen would be determined by the prescriber after weighing the potential benefits versus the potential risks associated with the use of this medication.
Should you have any questions about the drug, disease states treated, potential off-label uses, associated risks, or anything else, we encourage you to reach out to us. Our team at Bayview Pharmacy is composed of knowledgeable compounding pharmacists who are more than ready to assist.
Carbidopa 25 mg/Levodopa 100 mg Slow Release (MEM4) Oral Capsules are a type of medication that uses a controlled-release polymer called Methocel E4M to gradually release the encapsulated medication over an extended period of time. This provides sustained therapeutic effects, requires less frequent dosing, and improves patient compliance.
Methocel E4M is used to create a controlled-release profile for the medication. This means that the active ingredients are released slowly over an extended period of time. This approach provides sustained therapeutic effects and reduces the need for frequent dosing, which can improve patient compliance.
Slow release refers to the controlled and gradual release of the active ingredients over an extended period of time. This helps to maintain a steady level of the medication in the body, and can allow for less frequent dosing.
Slow release formulations can offer several benefits. This includes sustained therapeutic effects, less frequent dosing, and improved patient compliance, especially for medications that require a controlled and prolonged release profile.
A controlled-release polymer is a substance that can gradually release a drug or active ingredient over a specified period of time. Methocel E4M, used in this formulation, is an example of such a polymer.
Because it is a slow release medication, the dosing frequency will typically be less than with traditional medications. However, the exact dosing schedule should be guided by your doctor's instructions.
Like all medications, Carbidopa 25 mg/Levodopa 100 mg Slow Release (MEM4) Oral Capsules could potentially interact with other medications. Discuss all medications, supplements, and over-the-counter products you are taking with your health care provider to ensure safety.
While the slow release formulation has many benefits, it is not suitable for everyone. Patients with certain health conditions or who are on certain medications may not be able to use it. As with all medications, it should only be used under the supervision of a healthcare provider.
However, individual patient responses can vary.
No, opening or chewing the capsules can disrupt the controlled release profile of the medication, impacting its effectiveness. The capsules should be swallowed whole. If you have difficulty swallowing pills, consult with your healthcare provider for guidance.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
The conditions listed on this page are indications prescribers have ordered this preparation for. They are not FDA-approved indications, and listing them is not a statement that this preparation is effective for them.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice — discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NY, NJ, NH, FL, and ME. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
